DigestRedComo funciona
Red
/
Empresas
Cu
No verificado

Curium

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud Bienestar

22 Comunicados de prensa

Ver todos los comunicados de prensa
14/09/2026
Farmacéutica
Curium™ announces FDA approval of BEXLUTRY lutetium Lu 177 dotatate injection for adults with SSTR-positive GEP-NETs
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
10/08/2026
Farmacéutica
Medicina Salud Bienestar
Curium acquires Abscint SA, expanding PET radiodiagnostic pipeline in oncology
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
03/08/2026
Farmacéutica
Curium Announces Definitive Agreement to Merge with Lantheus
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
18/06/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Court victory paves the way for Curium’s plans to provide targeted radioligand therapy to U.S. patients with GEP-NETs
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
11/06/2026
Farmacéutica
Gestión empresarial/Administración de Empresas
Curium Group, PeptiDream and PDRadiopharma Announce Completion of Patient Dosing in Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
31/05/2026
Farmacéutica
Curium Announces a Strategic Investment of Over €32 million in Saclay, France
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
26/02/2026
Farmacéutica
Medicina Salud Bienestar
Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
03/02/2026
Farmacéutica
Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of Lu-PSMA-I&T for Prostate Cancer in Japan
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
07/01/2026
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0
22/12/2025
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Curium Announces First Commercial Doses of PYLCLARI® for Patients with Prostate Cancer in Poland
Fuente
Curium
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0